Serono and Genmab sign worldwide agreement to develop and commercialize Humax-TAC
04-May-2005
Under the agreement, Genmab will receive an upfront payment of USD 2 million and is entitled to potential milestone payments of up to USD 38 million and royalties on sales from any eventual commercialization of the product. Serono will be responsible for all future development costs for HuMax-TAC.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.